Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises A3P Biomedical in conjunction with directed share issue
Mandate

Vinge advises A3P Biomedical in conjunction with directed share issue

May 05, 2022 M&A

Vinge has advised A3P Biomedical in connection with an issue of shares amounting to SEK 400 million directed at Stena Sessan AB, TomEqt Private AB, Flerie Invest AB, Östersjöstiftelsen and Inbox Capital. A3P Biomedical specialises in advanced diagnostics of prostate cancer.

Vinge’s team primarily consisted of Johan Winnerblad, Rikard Lindahl, William Kåge, Lorin Arabi, Gabriel Chabo, Stojan Arnerstål, Arvid Axelryd and Olivia Belding.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025